에 대한 최신 뉴스 Kiromic BioPharma (OTC:KRBP) 주식

Kiromic BioPharma

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

Biotech

News

Legal

General

KRBP

사기 혐의로 51개월 징역형 선고 및 610만 달러 배상 명령받은 남성 라스베이거스에 거주하는 55세의 미칼라이 콘틸라이(Mykalai Kontilai)는 목요일에 장기 사기 계획에 연루된 혐의로 징역 51개월과 배상금으로 610만 달러를 지불하라는 선고를 받았다. 이전에 마이클 콘틸레(Michael Contile)로 알려진 콘틸라이는 콜렉터스 카페(Collector&#39;s Café)라고도 알려진 그의 회사인 콜렉터스 커피(Collector&#39;s Coffee Inc.)를 통해 투자 사기를 주도했다.

주간 금융 범죄: 콘틸라이에 51개월 형 선고, 키로믹은 중요 정보 미공개로 기소

KIROMIC BIOPHARMA INC by Kiromic BioPharma, Inc.

Kiromic BioPharma Inc

Rumors

Analyst Ratings

Trading Ideas

QUBT

Watching Quantum Computing; Traders Circulate Zacks Mentioned The Stock As A Buy

Citigroup analyst Steven Enders maintains Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) with a Buy and raises the price target from $4 to $5.

Price Target

EXFY

Citigroup Maintains Buy on Expensify, Raises Price Target to $5

Citigroup analyst Steven Enders maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Neutral and raises the price target from $64 to $73.

Citigroup Maintains Neutral on BlackLine, Raises Price Target to $73

WIIM

EWTX

Edgewise Therapeutics shares are trading higher after the company reported topline results from its Phase 2 CANYON trial of Sevasemten in individuals with Becker muscular dystrophy, with the trial meeting its primary endpoint.

CLVT

Clarivate shares are trading higher after the company announced a new $500 million share repurchase authorization.

LFST

LifeStance Health Group shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy.

Banco Macro shares are trading higher after Morgan Stanley upgraded the stock from Underweight to Overweight.

RDDT

UPDATE: Reddit Report Of "Confidential Submission Of Draft Registration Statement Related To Proposed Public Offering" Was Reported December 15, 2021.; Co Says "This Is An Old Blog Post Since We're Obviously A Public Company Already. You Can See It Has Been Removed And Was An Error"

Citigroup analyst Jason Gursky maintains Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) with a Buy and raises the price target from $4.05 to $5.

Citigroup Maintains Buy on Planet Labs, Raises Price Target to $5

Cabaletta Bio's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NYSE">CABA</a>) short percent of float has risen 25.26% since its last report. The company recently reported that it has 4.50 million shares sold short, which is 9.52% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cabaletta Bio Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363921_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cabaletta Bio has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cabaletta Bio's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cabaletta Bio's peer group average for short interest as a percentage of float is 8.59%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CABA

Peering Into Cabaletta Bio's Recent Short Interest

Rocket Lab USA's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NYSE">RKLB</a>) short percent of float has fallen 8.31% since its last report. The company recently reported that it has 49.28 million shares sold short, which is 13.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.71 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Rocket Lab USA Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363916_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Rocket Lab USA has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Rocket Lab USA's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Rocket Lab USA's peer group average for short interest as a percentage of float is 2.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

RKLB

(RKLB) - Analyzing Rocket Lab USA's Short Interest

Mobileye Global's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NYSE">MBLY</a>) short percent of float has fallen 3.8% since its last report. The company recently reported that it has 20.87 million shares sold short, which is 29.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Mobileye Global Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363911_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mobileye Global has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Mobileye Global's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Mobileye Global's peer group average for short interest as a percentage of float is 6.03%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MBLY

Peering Into Mobileye Global's Recent Short Interest

Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) has outperformed the market over the past 5 years by 30.12% on an annualized basis producing an average annual return of 43.71%. Currently, Viking Therapeutics has a market capitalization of $5.24 billion. 
Buying $100 In VKTX: If an investor had bought $100 of VKTX stock 5 years ago, it would be worth $596.07 today based on a price of $47.00 for VKTX at the time of writing.
<h3>Viking Therapeutics's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363908_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VKTX

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) with a Buy and maintains $37 price target.

Reiteration

PHAR

HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target

Morgan Stanley analyst Jorge Kuri upgrades Banco Macro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMA#NYSE">BMA</a>) from Underweight to Overweight and announces $12.5 price target.

Upgrades

Morgan Stanley Upgrades Banco Macro to Overweight, Announces $12.5 Price Target

Management

VLGEA

Village Super Market Appoints John J. Sumas As CEO; Nicholas J. Sumas Ii Appointed President & Chairman Of Board

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and maintains $34 price target.

VRDN

HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target

<a href="https://www.benzinga.com/24/11/42145521/netapp-analysts-raise-their-forecasts-after-strong-earnings">JPMorgan analyst Samik Chatterjee</a> upgraded the rating for NetApp Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Neutral to Overweight, while raising the price target from $150 to $160.
The company's revenue growth is likely to accelerate, driven by higher IT budgets for data centers and storage infrastructure of Enterprises looking to leverage AI use cases, according to JPMorgan.
The NetApp Thesis: Apart from higher enterprise spending, the company is also poised to benefit from its continued share gains from the recent pace of innovation, Chatterjee said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"In addition to recent expansion in product portfolio via addition of C-series products, we expect more launches in relation to C-series products, Block storage (ASA products) as well as products based on disaggregated architecture, which will further enhance the already robust product portfolio and drive growth," the analyst wrote.
In late November, NetApp reported <a href="https://www.benzinga.com/24/11/42145521/netapp-analysts-raise-their-forecasts-after-strong-earnings">better-than-expected quarterly results</a>.
The company's revenue growth could accelerate closer to the mid-point or higher-end of the company's latest guidance range, Chatterjee added.
"With resilient gross margins and operating leverage, we expect the modest revenue growth acceleration to be sufficient in relation to driving more material upsides to earnings estimates," Chatterjee further stated.
NTAP Price Action: Shares of NetApphad risen by 2.41% to $124.90 at the time of publication on Monday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/content/42459200/2-ai-stocks-that-gap-and-crapped-for-a-dip-buying-opportunity">2 AI Stocks That Gap and Crapped for a Dip Buying Opportunity</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

NTAP

NetApp Is Poised For Revenue Growth Acceleration With AI Spending: Analyst

Stryker's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) short percent of float has fallen 11.36% since its last report. The company recently reported that it has 4.24 million shares sold short, which is 1.17% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.25 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Stryker Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363022_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Stryker has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Stryker's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Stryker's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Stryker?

Verisk Analytics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRSK#NYSE">VRSK</a>) short percent of float has fallen 8.45% since its last report. The company recently reported that it has 2.43 million shares sold short, which is 1.95% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.94 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Verisk Analytics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734363017_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Verisk Analytics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Verisk Analytics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Verisk Analytics's peer group average for short interest as a percentage of float is 3.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

VRSK

Looking Into Verisk Analytics's Recent Short Interest

Kiromic Biopharma (KRBP) has released an update. Kiromic BioPharma, Inc. has secured a financial boost by issuing a Senior Secured Convertible Prom...

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

Kiromic BioPharma files to withdraw registration statement

Kiromic Biopharma (KRBP) has issued an announcement. Kiromic BioPharma, Inc. is gearing up to share its corporate vision and strategy through a ser...

Kiromic Biopharma Outlines Vision in Stakeholder Meetings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the first quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -$1.00.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/krbp-stock-earnings-kiromic-biopharma-for-q1-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024

The latest update is out from Kiromic Biopharma (KRBP). Kiromic BioPharma, Inc. has reached an agreement to transform $7.2 million of its high-inte...

Kiromic BioPharma's Strategic Financial Restructuring and Equity Shift

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the second quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/krbp-stock-earnings-kiromic-biopharma-for-q2-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024

Kiromic stock soars 65% on FDA fast track status for Deltacel

Kiromic BioPharma (KRBP) announced that it has entered into a settlement agreement with the U.S. SEC, resolving the previously disclosed SEC invest...

Kiromic BioPharma announces settlement of SEC investigation

The SEC announced that it has filed settled charges against Houston-based biotherapeutics company Kiromic BioPharma (KRBP), Inc., its former CEO, M...

SEC charges Kiromic Bio with misleading investors about status of FDA reviews

Press Releases

Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma's Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01

Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation

Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01

<h2 class="wp-block-heading">사기 혐의로 51개월 징역형 선고 및 610만 달러 배상 명령받은 남성</h2>
라스베이거스에 거주하는 55세의 미칼라이 콘틸라이(Mykalai Kontilai)는 목요일에 장기 사기 계획에 연루된 혐의로 징역 51개월과 배상금으로 610만 달러를 지불하라는 <a href="https://www.justice.gov/opa/pr/president-and-ceo-las-vegas-based-company-sentenced-role-investment-fraud-scheme-where-he" target="_blank" rel="noopener">선고</a>를 받았다. 이전에 마이클 콘틸레(Michael Contile)로 알려진 콘틸라이는 콜렉터스 카페(Collector&#8217;s Café)라고도 알려진 그의 회사인 콜렉터스 커피(Collector&#8217;s Coffee Inc.)를 통해 투자 사기를 주도했다.
미국 법무부에 따르면, 콘틸라이는 콜렉터스 커피의 CEO로서 2012년부터 2018년까지 회사가 스포츠 및 할리우드 기념품을 포함한 수집품을 위한 온라인 경매 플랫폼을 곧 출시할 것이라고 주장하여 투자자들을 속였다.
다음 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EA%B8%88%EC%9A%94%EC%9D%BC-%EC%83%81%EC%9C%84-5%EA%B0%9C-%ED%8A%B8%EB%A0%8C%EB%93%9C-%EC%A3%BC%EC%8B%9D-%EC%82%AC%EC%9A%B4%EB%93%9C%ED%95%98%EC%9A%B4%EB%93%9C-ai-%EA%B2%8C%EC%9E%84%EC%8A%A4/" target="_blank" rel="noopener">금요일의 인기 주식 5선: 사운드하운드 AI, 게임스탑, 룰루레몬은 무슨 일이 있었나요</a><a href="https://www.benzinga.com/24/12/42365711/fridays-top-5-trending-stocks-whats-going-on-with">?</a>
콘틸라이는 콜렉터스 커피 투자자로부터 약 2,300만 달러를 성공적으로 모금한 후, 약 610만 달러를 개인적인 용도로 횡령했다. 이 금액은 고급 상품, 아파트 및 차량 구매에 사용되었다.
미국 증권거래위원회(SEC)는 2017년경부터 콘틸라이를 조사하기 시작했으며, 이 과정에서 그는 서류를 위조하고 증언에서 거짓말을 하여 사법을 방해했다. 네바다와 콜로라도에서 기소에 직면한 콘틸라이는 러시아로 도주했다. 그는 2023년에 인터폴 적색 수배로 독일에서 체포되었고, 5월에 미국으로 송환되어 기소에 직면했다.
콘틸라이는 11월 21일에 전신 사기 혐의에 대해 유죄를 인정했다. 사건의 혐의에서 정부는 콜로라도 사건을 기각하기로 했다.
<h2 class="wp-block-heading">SEC, Kiromic BioPharma 및 CEO, CFO를 주요 정보 미공개로 기소</h2>
SEC는 화요일 키로믹 바이오파마(OTC:<a class="ticker" href="https://www.benzinga.com/stock/KRBP#OTC">KRBP</a>) 전 CEO 마우리치오 치리바-인터나티(Maurizio Chiriva-Internati)와 전 CFO 토니 톤타트(Tony Tontat)에 대해 2021년 7월 4,000만 달러를 모금한 후속 공모 전, 중, 후에 키로믹의 두 개의 암 치료제 후보에 대한 주요 정보를 공개하지 않은 혐의로 <a href="https://www.sec.gov/newsroom/press-releases/2024-189">합의된 기소</a>를 제기했다.
SEC의 명령에 따르면, 공모 2주 전에 식품의약국(FDA)가 키로믹 바이오파마에 두 약물 후보를 임상 보류에 올렸다고 통보했다.
키로믹 바이오파마는 SEC 제출 서류, 투자자 로드쇼 통화 또는 공모 이전의 실사 통화에서 FDA 임상 보류를 공개하지 않았다. 반면, 키로믹은 임상 보류의 가상적 위험과 키로믹의 사업에 미치는 잠재적 부정적 결과를 공개했다.
키로믹 바이오파마와 톤타트는 <a href="https://www.benzinga.com/pressreleases/24/12/b42295258/kiromic-biopharma-announces-settlement-of-previously-disclosed-sec-investigation">SEC의 기소를 별도의 행정 절차에서 합의</a>했으며, 치리바는 연방 지방 법원에서 기소를 합의했다. 키로믹은 자발적인 자진 신고, 협력 및 시정 조치에 비추어 민사 벌금을 부과받지 않았으며, 치리바와 톤타트은 각각 125,000달러와 20,000달러의 민사 벌금을 납부하기로 합의했다.
&#8220;이러한 해결책은 키로믹의 당시 두 고위 임원을 키로믹의 정보 공개 실패에 대해 책임을 지게 하는 동시에 키로믹의 자발적 자진 신고, 시정 조치, 사전 조치 및 직원에 대한 의미 있는 협력을 인정하는 적절한 균형을 이룬다&#8221;고 에릭 베르너(Eric Werner), SEC 포트워스 지역 사무소 이사가 말했다.

다음 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C%ED%97%AC%EC%8A%A4-%EB%B8%8C%EB%9D%BC%EC%9D%B4%EC%96%B8-%ED%86%B0%EC%8A%A8-%EC%82%AC%EB%A7%9D%EC%97%90-%EA%B9%8A%EC%9D%80-%EC%95%A0%EB%8F%84/" target="_blank" rel="noopener">유나이티드헬스케어 CEO 브라이언 톰슨, 뉴욕 호텔 밖에서 총격으로 사망</a></li>
</ul>
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Kiromic BioPharma

뉴스

에 대한 최신 뉴스 Kiromic BioPharma (OTC:KRBP) 주식

일요일, 12월 08, 2024

뉴스

파트너 / 기고자

벤징가 글로벌